drugset / Trial / NCT00662714

Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis

NCT00662714 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

Is oral therapy with Repaglinide equivalent to insulin therapy with three daily injections with respect to blood glucose control, weight and pulmonary function over 2 years in patients with cystic fibrosis and secondary diabetes mellitus? That is the question examined in the phase III trial.

Timeline

Start
2001-09
Primary completion
2011-12
Completion
2011-12

Outcome

Missed primary endpoint

paper mean difference between groups -0·4%, (95% CI -1·1 to 0·2 [-4·4 mmol/mol, -11·5 to 2·7], p=0·15). PMID 29199116 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Protein / enzyme biologic 0.05 iu/kg Other
Subject Repaglinide Small molecule 0.5 mg Oral